XML 13 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings (Accumulated Deficit) [Member]
Accumulated Other Comprehensive (Loss) [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2023 $ 8,126 $ 57 $ 27,807 $ (13,534) $ (2,697) $ (4,128) $ 7,506 $ 620
Beginning balance, shares at Dec. 31, 2023   1,227            
Net income (loss) (1,684)     (1,422)       (262)
Net income (loss) (1,422)           (1,422)  
Other comprehensive income (loss) (75)       (69)   (69) (6)
Other comprehensive income (loss) [1]         (72)      
Issuance of Shares, value 1 $ 1         1  
Issuance of Shares, shares   13            
Proceeds from exercise of options 7   7       7  
Stock-based compensation expense 89   89       89  
Dividend to non-controlling interest [2] (18)             (18)
Purchase of shares from redeemable non-controlling interests [3] (64)   (45)   (3)   (48) (16)
Ending balance at Sep. 30, 2024 6,383 $ 58 27,860 (14,956) (2,769) (4,128) 6,065 319
Ending balance, shares at Sep. 30, 2024   1,240            
Beginning balance at Jun. 30, 2024 6,563 $ 58 27,829 (14,519) (2,881) (4,128) 6,359 204
Beginning balance, shares at Jun. 30, 2024   1,239            
Net income (loss) (390)     (437)       47
Net income (loss) (437)           (437)  
Other comprehensive income (loss) 180       113   113 67
Issuance of Shares, shares   1            
Stock-based compensation expense 29   29       29  
Ending balance at Sep. 30, 2024 6,383 $ 58 27,860 (14,956) (2,769) (4,128) 6,065 319
Ending balance, shares at Sep. 30, 2024   1,240            
Beginning balance at Dec. 31, 2024 5,380 $ 58 27,764 (15,173) (3,148) (4,128) 5,373 7
Beginning balance, shares at Dec. 31, 2024   1,240            
Net income (loss) 931     930       1
Net income (loss) 930           930  
Other comprehensive income (loss) 700              
Other comprehensive income (loss) 673       673 [4]   673  
Issuance of Shares, shares   13            
Proceeds from exercise of options 3   3       3  
Stock-based compensation expense 106   106       106  
Dividend to non-controlling interest [5] (4)             (4)
Purchase of shares from redeemable non-controlling interests (38)              
Purchase of shares from redeemable non-controlling interests [6] 165   165       165  
Ending balance at Sep. 30, 2025 7,254 $ 58 28,038 (14,243) (2,475) (4,128) 7,250 4
Ending balance, shares at Sep. 30, 2025   1,253            
Beginning balance at Jun. 30, 2025 6,834 $ 58 28,003 (14,676) (2,431) (4,128) 6,827 7
Beginning balance, shares at Jun. 30, 2025   1,253            
Net income (loss) 434     433       1
Net income (loss) 433           433  
Other comprehensive income (loss) (44)              
Other comprehensive income (loss) (44)       (44)   (44)  
Stock-based compensation expense 34   34       34  
Dividend to non-controlling interest [5] (4)             (4)
Ending balance at Sep. 30, 2025 $ 7,254 $ 58 $ 28,038 $ (14,243) $ (2,475) $ (4,128) $ 7,250 $ 4
Ending balance, shares at Sep. 30, 2025   1,253            
[1] Amounts do not include a $6 million loss from foreign currency translation adjustments attributable to non-controlling interests.
[2] In connection with dividends to non-controlling interests in Teva’s business venture in Japan.
[3] Purchase of shares from non-controlling interests in a Teva’s subsidiary in Switzerland.
[4] Amounts do not include a $27 million gain from foreign currency translation adjustments attributable to redeemable and non-redeemable non-controlling interests.
[5] In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.
[6] In connection with the sale of Teva’s business venture in Japan. See note 17.